GaPP2

A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women

THE MAIN TRIAL FEATURES:

  • A randomised controlled trial.
  • Funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) program
  • Run by Prof Andrew Horne (Chief Investigator).
  • Birmingham Clinical Trials Unit at the University of Birmingham will be overseeing the administrative side of the Trial.
  • It is hoped that 300 women with a history of pelvic pain in whom a laparoscopy reveals no obvious pelvic pathology will be recruited
  • Participating women will be randomly allocated either Gabapentin or placebo and 50 women in Scotland will be will be recruited to an fMRI sub-study
  • The primary outcome is dual measures of worst and average pelvic pain scores assessed by a numerical rating scale (NRS) during the final 4 weeks of treatment (weeks 13-16 post-randomisation).

 

For the latest Patient Information Leaflet click here

GaPP2SOLOLOGORGBWEB  

Browser does not support script.